ASX Announcement

CHM CORE-NK vactosertib Phase 1b study re-opens enrolment

Published: 16/05/24, 09:27am (AEST)2 pages
Chimeric Therapeutics
CHM:ASXHealthcare

Recent CHM Announcements

Price Sensitive only